La Jolla, CA, United States of America

Andrew Hollands

USPTO Granted Patents = 6 

 

 

Average Co-Inventor Count = 5.8

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2019-2024

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Andrew Hollands

Introduction

Andrew Hollands is a notable inventor based in La Jolla, California. He has made significant contributions to the field of biotechnology, particularly in the development of polypeptides that target specific proteins. With a total of six patents to his name, Hollands has established himself as a key figure in his area of expertise.

Latest Patents

Hollands' latest patents include innovative discoveries such as CD33-binding polypeptides and their uses. These patents detail VHH-containing polypeptides that specifically bind to CD33, providing potential applications in therapeutic settings. Another significant patent focuses on CD123-binding polypeptides, which also involve VHH-containing polypeptides that bind to CD123, further expanding the possibilities for medical advancements.

Career Highlights

Throughout his career, Hollands has worked with prominent companies in the biotechnology sector, including Inhibrx, Inc. and Inhibrx Biosciences, Inc. His work in these organizations has allowed him to contribute to cutting-edge research and development in the field.

Collaborations

Hollands has collaborated with esteemed colleagues such as John C. Timmer and Brendan P. Eckelman. These partnerships have fostered a collaborative environment that enhances innovation and drives progress in their shared field of research.

Conclusion

Andrew Hollands is a distinguished inventor whose work in biotechnology has led to significant advancements in the development of therapeutic polypeptides. His contributions continue to influence the industry and pave the way for future innovations.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…